Cardiovascular effects of relaxin: from basic science to clinical therapy
- PMID: 19935741
- DOI: 10.1038/nrcardio.2009.198
Cardiovascular effects of relaxin: from basic science to clinical therapy
Abstract
Although substantial advances have been achieved in recent decades in the clinical management of heart diseases, new therapies that provide better or additional efficacy with minimal adverse effects are urgently required. Evidence that has accumulated since the 1990s indicates that the peptide hormone relaxin has multiple beneficial actions in the cardiovascular system under pathological conditions and, therefore, holds promise as a novel therapeutic intervention. Clinical trials for heart failure therapy using relaxin revealed several beneficial actions. Here we review findings from mechanistic and applied research in this field, comment on the outcomes of recent phase I/II clinical trails on patients with heart failure, and highlight settings of cardiovascular diseases where relaxin might be effective.
Similar articles
-
Relaxin: a new approach for the treatment of acute congestive heart failure.Cardiol Rev. 2010 Nov-Dec;18(6):305-12. doi: 10.1097/CRD.0b013e3181f493e3. Cardiol Rev. 2010. PMID: 20926940 Review.
-
The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.Am J Physiol Regul Integr Comp Physiol. 2013 Sep 15;305(6):R559-65. doi: 10.1152/ajpregu.00528.2012. Epub 2013 Jul 24. Am J Physiol Regul Integr Comp Physiol. 2013. PMID: 23883673 Free PMC article. Review.
-
Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives.Clin Res Cardiol. 2024 Aug;113(8):1137-1150. doi: 10.1007/s00392-023-02305-1. Epub 2023 Sep 18. Clin Res Cardiol. 2024. PMID: 37721595 Free PMC article. Review.
-
Peptide hormone relaxin: from bench to bedside.Am J Physiol Regul Integr Comp Physiol. 2018 Jun 1;314(6):R753-R760. doi: 10.1152/ajpregu.00276.2017. Epub 2018 Feb 7. Am J Physiol Regul Integr Comp Physiol. 2018. PMID: 29412692 Review.
-
Relaxin: review of biology and potential role in treating heart failure.Curr Heart Fail Rep. 2010 Jun;7(2):75-82. doi: 10.1007/s11897-010-0010-z. Curr Heart Fail Rep. 2010. PMID: 20424993 Free PMC article. Review.
Cited by
-
Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1.Nat Commun. 2013;4:1953. doi: 10.1038/ncomms2953. Nat Commun. 2013. PMID: 23764525 Free PMC article.
-
Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.PLoS One. 2012;7(8):e42714. doi: 10.1371/journal.pone.0042714. Epub 2012 Aug 22. PLoS One. 2012. PMID: 22936987 Free PMC article.
-
Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis.Medicine (Baltimore). 2018 Jun;97(25):e11010. doi: 10.1097/MD.0000000000011010. Medicine (Baltimore). 2018. PMID: 29923986 Free PMC article.
-
Serelaxin induces Notch1 signaling and alleviates hepatocellular damage in orthotopic liver transplantation.Am J Transplant. 2018 Jul;18(7):1755-1763. doi: 10.1111/ajt.14706. Epub 2018 Mar 23. Am J Transplant. 2018. PMID: 29464890 Free PMC article.
-
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445. Br J Pharmacol. 2013. PMID: 24517644 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases